Change Healthcare vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Eli Lilly leads in AI visibility (81 vs 60)
Change Healthcare logo

Change Healthcare

ChallengerHealthcare

Revenue Cycle

Healthcare clearinghouse processing 15B+ annual claims acquired by Optum; 2024 ransomware attack caused $1B+ provider disruption and sparked nationwide healthcare cybersecurity overhaul.

AI VisibilityBeta
Overall Score
B60
Category Rank
#122 of 596
AI Consensus
82%
Trend
stable
Per Platform
ChatGPT
56
Perplexity
55
Gemini
62

About

Change Healthcare (now part of Optum) is a healthcare technology company providing claims processing, payment management, network intelligence, and clinical decision support tools to the US healthcare ecosystem — connecting payers, providers, pharmacies, and patients through data and technology infrastructure. Change Healthcare was acquired by UnitedHealth Group's Optum subsidiary in October 2022 following a lengthy regulatory review that included a DOJ lawsuit to block the acquisition on antitrust grounds.

Full profile
Eli Lilly logo

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A81
Category Rank
#17 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
75
Gemini
77

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

60
Overall Score
81
#122
Category Rank
#17
82
AI Consensus
71
stable
Trend
stable
56
ChatGPT
80
55
Perplexity
75
62
Gemini
77
60
Claude
86
60
Grok
85

Key Details

Category
Revenue Cycle
General
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Change Healthcare
Revenue Cycle

Integrations

Eli Lilly is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.